Cromwell Holdings LLC Boosts Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Cromwell Holdings LLC boosted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 276.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 673 shares of the medical equipment provider’s stock after purchasing an additional 494 shares during the period. Cromwell Holdings LLC’s holdings in Zimmer Biomet were worth $71,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Blue Trust Inc. raised its stake in shares of Zimmer Biomet by 165.3% in the 3rd quarter. Blue Trust Inc. now owns 1,719 shares of the medical equipment provider’s stock valued at $187,000 after acquiring an additional 1,071 shares during the period. Eastern Bank purchased a new position in shares of Zimmer Biomet in the 3rd quarter valued at $382,000. BLB&B Advisors LLC raised its stake in shares of Zimmer Biomet by 2.1% in the 3rd quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock valued at $529,000 after acquiring an additional 100 shares during the period. Courier Capital LLC raised its stake in shares of Zimmer Biomet by 46.1% in the 3rd quarter. Courier Capital LLC now owns 6,054 shares of the medical equipment provider’s stock valued at $654,000 after acquiring an additional 1,910 shares during the period. Finally, International Assets Investment Management LLC raised its stake in shares of Zimmer Biomet by 19,988.0% in the 3rd quarter. International Assets Investment Management LLC now owns 107,471 shares of the medical equipment provider’s stock valued at $11,601,000 after acquiring an additional 106,936 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $103.64 on Friday. The firm has a market cap of $20.63 billion, a P/E ratio of 23.29, a P/E/G ratio of 1.95 and a beta of 1.02. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The firm has a fifty day moving average of $105.90 and a two-hundred day moving average of $107.48.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the company posted $2.20 EPS. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were given a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.93%. Zimmer Biomet’s payout ratio is currently 21.57%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ZBH shares. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their target price for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Raymond James cut their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. JMP Securities reissued a “market outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 7th. Truist Financial reaffirmed a “hold” rating and set a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Finally, Royal Bank of Canada lowered their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and an average price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.